—Focus on applying in situ tissue quantitative proteomic data to advance several Lilly pharmaceutical development programs—

NEW HAVEN, Conn., October 13, 2005 – HistoRx, Inc. and Eli Lilly and Company (NYSE: LLY) have entered into a collaboration to apply the HistoRx AQUA™ platform for quantitative pathology analysis. The collaboration calls for the use of the AQUA™ platform to generate in situ proteomic information to elucidate different aspects of Lilly’s drug discovery and development pathway. Terms of the collaboration were not disclosed.

Robert A. Curtis, Pharma.D., president and CEO of HistoRx, Inc. noted, “This collaboration is an illustration of the broad utility of the AQUA platform, as the technology is applicable across multiple areas of Lilly’s drug discovery and development efforts. The information afforded by the AQUA™ system allows greater insight into the role of protein expression in disease and how it will affect patient stratification and drug targeting, moving us closer to a new era of personalized, molecular medicine.”

Dr. Curtis also noted that the importance of understanding where in a specific sub-cellular compartment a particular protein is expressed, in addition to just merely knowing the protein’s level of expression, is beginning to build momentum in the scientific community as a key driver for understanding disease.

ABOUT AQUA™

The AQUA™ platform represents the first integrated automated fluorescence-based imaging platform to identify and quantitate tissue biomarkers in high throughput tissue microarray format or in whole tissue slices. The AQUA™ platform simultaneously measures changes in expression levels of multiple protein biomarkers at the subcellular level while maintaining the spatial relationship between the targets of interest.

ABOUT HISTORX, INC.
HistoRx, Inc. is introducing a new generation of advanced quantitative diagnostic products for research and clinical pathology markets based on the company’s proprietary integrated tissue analysis platform, AQUA™, which the company developed from technology pioneered at the Yale University School of Medicine. Initially, HistoRx is providing contract services to the pharmaceutical and biotechnology industries while selectively licensing its technologies to leading academic and not-for-profit research institutions. Simultaneously, the company is advancing development of proprietary fluorescence-based molecular diagnostic tests for use with its AQUA™ platform that will enable biologically based selection of patients who are most likely to benefit from specific therapies. HistoRx is based in New Haven, Conn. For more information, please visit www.historx.com